ClinicalTrials.gg

TargetBeta

DRD2

dopamine receptor D2 · also D2R · Dopamine receptors

15 programs in company-led studies act on DRD2, from 11 companies: 3 in phase 3, 10 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
iloperidoneruleVanda Pharmaceuticalsphase 4153 runningHTR2AChEMBL
AripiprazoleruleOtsukaphase 41312 runningHTR1A, HTR2AChEMBL
lurasidoneruleSumitomo Pharmaphase 4522 runningHTR2AChEMBL
CabergolineruleChangchun GeneScience Pharmaceuticalphase 482 running–ChEMBL
RisperidoneruleJohnson & Johnsonphase 41111 runningHTR2A, HTR2CChEMBL
paliperidoneruleJohnson & Johnsonphase 41061 runningHTR2AChEMBL
OlanzapineruleEli Lillyphase 4761 runningDRD3, DRD4, HTR2A, HTR2CChEMBL
rotigotineruleUCBphase 4641 runningDRD3, DRD4ChEMBL
PramipexoleruleBoehringer Ingelheimphase 4441 runningDRD3, DRD4ChEMBL
brexpiprazoleruleOtsukaphase 4700 runningHTR1A, HTR2AChEMBL
lumateperoneruleJohnson & Johnsonphase 3256 runningHTR2A, SLC6A4ChEMBL
cariprazineruleAbbViephase 3414 runningDRD3ChEMBL
pridopidinerulePrileniaphase 3102 running–ChEMBL
ABBV-932AbbViephase 2103 runningDRD3, HTR1Athe company's pipeline
zeltiproneruleJazz Pharmaceuticalsphase 233 running–NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.